Decade In Review: C-Suite Shifts At Family-Owned Indian Firms
Mix Of Internal, External Expertise
Executive Summary
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
You may also be interested in...
India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
Strides’ New CEO Is Former Cipla COO
Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.
Events And Losses That Shook India Pharma In The Decade
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.